FDA Approves dapagliflozin for treating Chronic Kidney Disease Dr Kartikeya Kohli1 May 2021 7:46 AM ISTThe U.S. Food and Drug Administration has approved dapagliflozin oral tablets to reduce the risk of kidney function decline, kidney failure,...
SGLT2 inhibitor dapagliflozin significantly impacts urine metabolome in diabetics: Study Medha Baranwal18 April 2021 2:27 PM ISTGreece: Dapagliflozin treatment is associated with a significant change in urine metabolome in patients with type 2 diabetes (T2D) independent of...
Dapagliflozin Reduces Blood Pressure by Vasodilation, Finds Study MD Bureau25 March 2021 7:58 PM ISTHypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular disease. Dapagliflozin improves both blood sugar and systolic...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 4:10 PM ISTNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
Zydus Cadila net profit rises 41 percent to Rs 527 crore in Q3 Ruchika Sharma8 Feb 2021 10:00 AM ISTAhmedabad: Pharmaceutical major Zydus Cadila said on Friday its profit after tax was up by 41 per cent to Rs 527 crore in Q3 FY21 as compared to the...
AstraZeneca gets CDSCO nod for Dapagliflozin in CKD MD Bureau17 Jan 2021 3:30 PM ISTNew Delhi: The Subject Expert Committee (SEC), operative under the Central Drugs Standard Control Organization (CDSCO), has given its nod to...
Dapagliflozin going off-patent- NPPA brings Dapagliflozin, Metformin Combination under price control Farhat Nasim14 Jan 2021 5:15 PM ISTNew Delhi: With the popular antidiabetic drug, Dapagliflozin going off-patent, the apex drug price regulator, National Pharmaceutical Pricing...
NPPA fixes retail price of 7 formulations, Details Ruchika Sharma9 Jan 2021 3:24 PM ISTNew Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India...
AstraZeneca gets USFDA Priority Review for Farxiga to treat chronic kidney disease Ruchika Sharma7 Jan 2021 12:00 PM ISTCKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis...
No impact of dapagliflozin on short-term BP variability in diabetics: Study Medha Baranwal10 Dec 2020 10:30 AM ISTGreece: The use of SGLT2 inhibitor dapagliflozin does not affect short-term blood pressure variability (BPV) in type 2 diabetes (T2D) patients,...
Dapagliflozin, metformin, or exercise didn't decrease plasma glucagon in individuals with prediabetes Dr. Nandita Mohan25 Nov 2020 12:30 PM ISTResearchers have found that in individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin, or exercise was not associated...
Dapagliflozin NOT off Patent, says AstraZeneca Medical Dialogues Bureau23 Nov 2020 3:14 PM ISTNew Delhi: The arrival of SGLT-2 inhibitors or Glifozins, has brought a major change in the management of Diabetes in the past decade. Numerous pharma...
